Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis?
Hypokalaemic periodic paralysis (hypoPP) is the archetypal skeletal muscle channelopathy caused by dysfunction of one of two sarcolemmal ion channels, either the sodium channel Nav1.4 or the calcium channel Cav1.1. Clinically, hypoPP is characterised by episodes of often severe flaccid muscle paralysis, in which the muscle fibre membrane becomes electrically inexcitable, and which may be precipitated by low serum potassium levels. Initial functional characterisation of hypoPP mutations failed to adequately explain the pathomechanism of the disease. Recently, as more pathogenic mutations involving loss of positive charge have been identified in the S4 segments of either channel, the hypothesis that an abnormal gating pore current may be important has emerged. Such an aberrant gating pore current has been identified in mutant Nav1.4 channels and has prompted potentially significant advances in this area. The carbonic anhydrase inhibitor acetazolamide has been used as a treatment for hypokalaemic periodic paralysis for over 40 years but its precise therapeutic mechanism of action is unclear. In this review we summarise the recent advances in the understanding of the molecular pathophysiology of hypoPP and consider how these may relate to the reported beneficial effects of acetazolamide. We also consider potential areas for future therapeutic development.
Matthews
E
E
MRC Centre for Neuromuscular Disease, University College London Hospitals/University College London, UCL, Institute of Neurology, London, UK.
Hanna
M G
MG
D000086:Acetazolamide / Q000627:therapeutic use; D000818:Animals; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D002256:Carbonic Anhydrases / Q000235:genetics / Q000502:physiology; D053447:Channelopathies / Q000235:genetics* / Q000473:pathology*; D006801:Humans; D020514:Hypokalemic Periodic Paralysis / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D015640:Ion Channel Gating / Q000235:genetics* / Q000502:physiology*; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D018908:Muscle Weakness / Q000188:drug therapy / Q000209:etiology; D009135:Muscular Diseases / Q000235:genetics* / Q000473:pathology*; D024681:Potassium Channels, Calcium-Activated / Q000502:physiology
D002257:Carbonic Anhydrase Inhibitors; D007527:Isoenzymes; D024681:Potassium Channels, Calcium-Activated; D002256:Carbonic Anhydrases; D000086:Acetazolamide